Be Careful With Florida

You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news. We post this and all of the newsletters on our website here.


Cannabis stocks are rallying hard in 2024. The New Cannabis Ventures Global Cannabis Stock Index is up by 33.5% so far. Of course, a major development is playing out: rescheduling. If cannabis is moved from Schedule 1 to Schedule 3, then 280E taxation will end, which will be very good for the American cannabis companies that have been paying it.

The American cannabis companies are doing well, but they aren’t the only part of the market firing forward. The NCV American Cannabis Operator Index has gained 35.1%, only slightly higher than the Global Cannabis Stock Index.  As we discussed last week, certain Canadian LPs that are in the GCSI are doing so much better than the index and the American operators. Cannabis investors should avoid certain Canadian LPs.

While rescheduling looks like it will take place, which should be good for the MSOs due to tax reduction and improved cash flow, we remind readers that there may be some things that will not be so positive. We have a fairly large exposure to MSOs in the model portfolio at 420 Investor. but we are avoiding some of the largest ones. The five Tier 1 names are up dramatically in 2024 and over the past year, especially Trulieve:

Each of these stocks has outperformed the Global Cannabis Stock Index, up 39.2%, over the past year. A year ago, Trulieve was very out of favor. Going back to the end of 2022, it is up a lot, but it is not the leader:

Since the end of 2022, the Global Cannabis Stock Index has gained 11.5%, so these large MSOs are all up by at least twice as much. The two leaders among the five largest MSOs are both big in Florida, which is a large medical-cannabis state that is vertically-integrated. Trulieve has 136 dispensaries, while Verano operates 75. The two of them have about 1/3 of the 635 open dispensaries in the state.

Investors have been very excited by the chances of the voters in Florida approving a ballot initiative in November that would allow adult-use legalization. The Supreme Court of Florida gave the go-ahead in early April, overruling a challenge. The MSOs in the state joined Trulieve in funding support for the amendment, which will require 60% of voters approving it to pass.

In addition to Trulieve and Verano, AYR Wellness and Curaleaf are big operators in the Florida medical cannabis market, with 125 stores between the two of them. The four of these, then, have 336 dispensaries in Florida, which is 53% of all dispensaries in the state. AYR Wellness, which is up 59.2% in 2024, has gained 139.2% since the end of 2022, ahead of the five largest MSOs.

We began writing about the Florida medical market recently. The state provides an update each week with unit volumes for all of its participants. Typically, these reports are released on Friday for the week ending on Thursday. The past report, though, was late to actually hit the website. Instead of last Friday, it was published on the OMMU website on Tuesday. The report showed a new all-time low in growth of patients, which expanded just 7.3% from a year ago. When we updated the BDSA data earlier this month, we shared that Florida revenue was up only 1.8% from a year earlier in March. This was a record low too.

It’s not clear that Florida voters will approve adult-use legalization in November. If they don’t, we think the market will not be happy with a mature medical market that is slowing and competitive. If they do, it’s not yet clear that the four largest operators will win going forward. Investors should be careful in our view with the big Florida operators.

New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most important content from this week:


Michigan Cannabis Sales Slow in April

Financial Reports

AYR Wellness Q1 Revenue Flat From a Year Ago

Cresco Labs Q1 Revenue Falls 5%

To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.

Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer the Canadian Cannabis LP Index, the American Cannabis Operator Index and the Ancillary Cannabis Index.

View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks.

Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.

Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.



Exclusive article by Alan Brochstein, CFA
Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter